Details

Autor(en) / Beteiligte

• Dilmore, Amanda Hazel
• Martino, Cameron
• Neth, Bryan J
• West, Kiana A
• Zemlin, Jasmine
• Rahman, Gibraan
• Panitchpakdi, Morgan
• Meehan, Michael J
• Weldon, Kelly C
• Blach, Colette
• Schimmel, Leyla
• Kaddurah-Daouk, Rima
• Dorrestein, Pieter C
• Knight, Rob
• Craft, Suzanne

Titel

Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease

Ist Teil von

• Alzheimer's & dementia, 2023-11, Vol.19 (11), p.4805-4816

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• The ketogenic diet (KD) is an intriguing therapeutic candidate for Alzheimer's disease (AD) given its protective effects against metabolic dysregulation and seizures. Gut microbiota are essential for KD-mediated neuroprotection against seizures as well as modulation of bile acids, which play a major role in cholesterol metabolism. These relationships motivated our analysis of gut microbiota and metabolites related to cognitive status following a controlled KD intervention compared with a low-fat-diet intervention. Prediabetic adults, either with mild cognitive impairment (MCI) or cognitively normal (CN), were placed on either a low-fat American Heart Association diet or high-fat modified Mediterranean KD (MMKD) for 6 weeks; then, after a 6-week washout period, they crossed over to the alternate diet. We collected stool samples for shotgun metagenomics and untargeted metabolomics at five time points to investigate individuals' microbiome and metabolome throughout the dietary interventions. Participants with MCI on the MMKD had lower levels of GABA-producing microbes Alistipes sp. CAG:514 and GABA, and higher levels of GABA-regulating microbes Akkermansia muciniphila. MCI individuals with curcumin in their diet had lower levels of bile salt hydrolase-containing microbes and an altered bile acid pool, suggesting reduced gut motility. Our results suggest that the MMKD may benefit adults with MCI through modulation of GABA levels and gut-transit time.